Commercial Underwriting Software

Scienaptic

Consumer decisioning

Scienaptic sells AI credit decisioning to credit unions and banks for consumer and retail lending, with fraud and anomaly detection at origination and vehicle loan pricing. It documents no commercial, business or member business lending capability, and no statement spreading, debt service coverage or business credit analysis appears anywhere on its site.

Last verified

What it is

Scienaptic sells AI credit decisioning to credit unions and banks, positioned around financial inclusion and widening approvals to thin-file members. The product line that can be verified is consumer and retail only: underwriting, fraud and anomaly detection at loan origination, and vehicle loan pricing. No page names commercial lending, business lending, member business lending or small business, and there is no statement spreading, debt service coverage or business credit analysis content anywhere. Its solutions path returns a 404 and its underwriting page returned no readable body text, so commercial support is unverified rather than actively disproven, and either way there is nothing published a commercial credit team could evaluate. The sales motion is real and current, with a steady cadence of named credit union wins published through August 2026, and its CUSO structure with credit union investors often eases due diligence for a credit union buyer. One published figure should not be repeated: an asset total appearing in its 2026 material is not credible against its own 2024 boilerplate, implying an order-of-magnitude increase in assets served on five more customers, so this site prints neither number.

What it does

  • AI credit decisioning for consumer and retail lending
  • Fraud and anomaly detection bundled at loan origination rather than sold separately
  • Vehicle loan pricing as a distinct capability
  • CUSO structure with credit union investors behind it

Strengths

  • Founding year and headquarters are cleanly verifiable on primary sources, which is less common in this category than it should be
  • A high, steady cadence of named credit union wins through August 2026, which is real evidence of a working sales motion
  • CUSO structure with credit union investors aligns incentives for a credit union buyer and often shortens due diligence
  • Fraud and anomaly detection at origination comes bundled with decisioning rather than as a second purchase

Considerations

  • No verifiable commercial or business lending capability. The entire documented product surface is consumer, and member business lending is never named
  • Its own published metrics contradict each other badly enough that the more recent asset figure is not credible, so neither figure is repeated here
  • Deployment model and pricing are undocumented, and two product URLs return either a 404 or no readable page body
  • Heavy concentration in small community credit unions means there is no evidence it scales to complex commercial credit

Best when

The goal is widening consumer approvals, and commercial credit is handled by a different vendor entirely.

Scienaptic FAQ

Does Scienaptic support member business lending?

Nothing published says so. Member business lending, commercial lending and small business are named nowhere on its site, and the documented surface is consumer decisioning, fraud detection and vehicle loan pricing. A credit union building an MBL programme needs a different product for the credit analysis.

Why is its asset figure disputed?

Because its own numbers do not reconcile. A 2024 statement of institutions served and combined assets sits against a 2026 figure implying an order-of-magnitude jump in assets on a handful more customers. This site prints neither figure, and a buyer should ask for the current number in writing.

What is Scienaptic genuinely good at?

Widening consumer and vehicle lending approvals at community credit unions, with fair-access framing and a steady record of named wins. Judged on that job it is a credible vendor. Judged as commercial underwriting software it has nothing published to evaluate.